Evidence map›Paper›PMID 21879735›Full record

ArticleMolecular pharmaceutics2011

Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry.

Alamelu Mahalingam, Anthony R Geonnotti, Jan Balzarini, Patrick F Kiser

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Antimicrobial agents and chemotherapy · 2021
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Long-acting slow effective release antiretroviral therapy.Expert opinion on drug delivery · 2017
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Recent Progress in Lectin-Based Biosensors.Materials (Basel, Switzerland) · 2015
    Review
  13. Article
  14. Article
  15. Molecular architecture and therapeutic potential of lectin mimics.Advances in carbohydrate chemistry and biochemistry · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alamelu MahalingamDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84112-5820, United States.
Anthony R Geonnotti
Jan Balzarini
Patrick F Kiser

Funding

Bioresponsive Microbicides for AIDS PreventionR21AI062445 · NIAID · UNIVERSITY OF UTAH · PI KISER, PATRICK FRANKLIN · 2004 to 2005
$430k
NIAID NIH HHS R21 AI062445NIAID NIH HHS R21-AI062445
6 · The paper itself

Abstract

Lectins derived from plant and microbial sources constitute a vital class of entry inhibitors that target the oligomannose residues on the HIV envelope gp120. Despite their potency and specificity, success of lectin-based entry inhibitors may be impeded by high manufacturing costs, formulation and potential mitogenicity. Therefore, there exists a gap in the HIV microbicides pipeline that underscores the need for mass producible, synthetic, broad-spectrum, and biocomptabile inhibitors of HIV entry. Here, we present the development of a polymeric synthetic lectin, based on benzoboroxole (BzB), which exhibits weak affinity (∼25 M(-1)) for nonreducing sugars, similar to those found on the HIV envelope. High molecular weight BzB-functionalized polymers demonstrated antiviral activity that increased with an increase in ligand density and molecular weight of the polymer construct, revealing that polyvalency improves activity. Polymers showed significant increase in activity from 25 to 75 mol % BzB functionalization with EC(50) of 15 μM and 15 nM, respectively. A further increase in mole functionalization to 90% resulted in an increase of the EC(50) (59 ± 5 nM). An increase in molecular weight of the polymer at 50 mol % BzB functionalization showed a gradual but significant increase in antiviral activity, with the highest activity seen with the 382 kDa polymer (EC(50) of 1.1 ± 0.5 nM in CEM cells and 11 ± 3 nM in TZM-bl cells). Supplementing the polymer backbone with 10 mol % sulfonic acid not only increased the aqueous solubility of the polymers by at least 50-fold but also demonstrated a synergistic increase in anti-HIV activity (4.0 ± 1.5 nM in TZM-bl cells), possibly due to electrostatic interactions between the negatively charged polymer backbone and the positively charged V3-loop in the gp120. The benzoboroxole-sulfonic acid copolymers showed no decrease in activity in the presence of a seminal concentration of fructose (p > 0.05). Additionally, the copolymers exhibit minimal, if any, effect on the cellular viability, barrier properties, or cytokine levels in human reconstructed ectocervical tissue after 3 days of repeated exposure and did not show pronounced activity against a variety of other RNA and DNA viruses.

Indexed as

Antiviral AgentsBoronic AcidsCalorimetryHIVHumansLectinsModels, MolecularPolymersVirus InternalizationAntiviral Agentsbenzeneboronic acidBoronic AcidsLectinsPolymers

Identifiers

PMID21879735
PMCPMC3445258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.